Changes in the rate of leucine-rich glioma-inactivated 1 seropositivity during the COVID-19 lockdown
Several reports suggest autoantibody-associated neurologic conditions, such as autoimmune encephalitis and myelin-oligodendrocyte glycoprotein (MOG) antibody–associated diseases, may be triggered by the COVID-19 pandemic and associated vaccinations.1,2 Conversely, public health measures, including l...
Main Authors: | , , , , |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Medical Association
2023
|
_version_ | 1797109900632915968 |
---|---|
author | Handel, AE Palace, J Bateman, E Waters, P Irani, SR |
author_facet | Handel, AE Palace, J Bateman, E Waters, P Irani, SR |
author_sort | Handel, AE |
collection | OXFORD |
description | Several reports suggest autoantibody-associated neurologic conditions, such as autoimmune encephalitis and myelin-oligodendrocyte glycoprotein (MOG) antibody–associated diseases, may be triggered by the COVID-19 pandemic and associated vaccinations.1,2 Conversely, public health measures, including lockdowns, might reduce the incidence of immune-mediated neurologic disorders through fewer antecedent infective agents.3 To understand real-world implications of COVID-19–instigated public health measures on the most common autoantibody-mediated neurologic conditions, we compared positivity rates of the most prevalent neuroglial surface autoantibodies between prepandemic (2019) and postpandemic (2020) time points. We hypothesized that lockdown measures may reduce the rates of neurologic autoantibody positivity. |
first_indexed | 2024-03-07T07:47:38Z |
format | Journal article |
id | oxford-uuid:e1446c48-803c-4659-8f07-8fc39061f2ea |
institution | University of Oxford |
language | English |
last_indexed | 2024-03-07T07:47:38Z |
publishDate | 2023 |
publisher | American Medical Association |
record_format | dspace |
spelling | oxford-uuid:e1446c48-803c-4659-8f07-8fc39061f2ea2023-06-13T09:27:24ZChanges in the rate of leucine-rich glioma-inactivated 1 seropositivity during the COVID-19 lockdownJournal articlehttp://purl.org/coar/resource_type/c_545buuid:e1446c48-803c-4659-8f07-8fc39061f2eaEnglishSymplectic ElementsAmerican Medical Association2023Handel, AEPalace, JBateman, EWaters, PIrani, SRSeveral reports suggest autoantibody-associated neurologic conditions, such as autoimmune encephalitis and myelin-oligodendrocyte glycoprotein (MOG) antibody–associated diseases, may be triggered by the COVID-19 pandemic and associated vaccinations.1,2 Conversely, public health measures, including lockdowns, might reduce the incidence of immune-mediated neurologic disorders through fewer antecedent infective agents.3 To understand real-world implications of COVID-19–instigated public health measures on the most common autoantibody-mediated neurologic conditions, we compared positivity rates of the most prevalent neuroglial surface autoantibodies between prepandemic (2019) and postpandemic (2020) time points. We hypothesized that lockdown measures may reduce the rates of neurologic autoantibody positivity. |
spellingShingle | Handel, AE Palace, J Bateman, E Waters, P Irani, SR Changes in the rate of leucine-rich glioma-inactivated 1 seropositivity during the COVID-19 lockdown |
title | Changes in the rate of leucine-rich glioma-inactivated 1 seropositivity during the COVID-19 lockdown |
title_full | Changes in the rate of leucine-rich glioma-inactivated 1 seropositivity during the COVID-19 lockdown |
title_fullStr | Changes in the rate of leucine-rich glioma-inactivated 1 seropositivity during the COVID-19 lockdown |
title_full_unstemmed | Changes in the rate of leucine-rich glioma-inactivated 1 seropositivity during the COVID-19 lockdown |
title_short | Changes in the rate of leucine-rich glioma-inactivated 1 seropositivity during the COVID-19 lockdown |
title_sort | changes in the rate of leucine rich glioma inactivated 1 seropositivity during the covid 19 lockdown |
work_keys_str_mv | AT handelae changesintherateofleucinerichgliomainactivated1seropositivityduringthecovid19lockdown AT palacej changesintherateofleucinerichgliomainactivated1seropositivityduringthecovid19lockdown AT batemane changesintherateofleucinerichgliomainactivated1seropositivityduringthecovid19lockdown AT watersp changesintherateofleucinerichgliomainactivated1seropositivityduringthecovid19lockdown AT iranisr changesintherateofleucinerichgliomainactivated1seropositivityduringthecovid19lockdown |